SCHEMBL10155593

SCHEMBL10155593

CNC(=O)Nc1ccc(S(=O)(=O)NC)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.69
RAB9A P51151 4/20 0.61
GAA P10253 3/20 0.61
MEN1 O00255 1/20 0.61
NPC1 O15118 2/20 0.58
NAMPT P43490 1/20 0.58
ALDH1A1 P00352 1/20 0.56
BDKRB1 P46663 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
TP53 P04637 1/20 0.54
CA12 O43570 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
CA14 Q9ULX7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214047 0.86 KMT2A (0.58) KMT2ARAB9AGAAMEN1NPC1
SCHEMBL12049668 0.83 KMT2A (0.71) KMT2AALDH1A1
SCHEMBL1102020 0.83 CA1 (0.73) KMT2ARAB9AGAAMEN1ALDH1A1
SCHEMBL16705173 0.83 KMT2A (0.71) KMT2AALDH1A1BDKRB1CA1CA2
SCHEMBL5722112 0.83 LMNA (0.62) KMT2AMEN1NPC1ALDH1A1SMN1; SMN2
SCHEMBL10155599 0.82 ALDH1A1 (0.78) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL6252334 0.81 KMT2A (1.00) KMT2AMEN1ALDH1A1CA1CA2
SCHEMBL4969968 0.81 KMT2A (0.69) KMT2AMEN1ALDH1A1BDKRB1CA1
SCHEMBL4002880 0.80 MAPT (0.68) KMT2ARAB9AGAAMEN1NPC1
SCHEMBL12049681 0.80 KMT2A (0.59) KMT2ARAB9AGAAMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193164-B2 Organic compounds NOVARTIS AG (CH) 2012-06-05 US disclosed
US-8193164-B2 Organic compounds NOVARTIS AG (CH) 2012-06-05 US disclosed
US-8071565-B2 Purine derivatives as a2a agonists NOVARTIS AG (CH) 2011-12-06 US disclosed
US-8071565-B2 Purine derivatives as a2a agonists NOVARTIS AG (CH) 2011-12-06 US disclosed
US-20100240680-A1 Purine derivatives as a2a agonists NOVARTIS AG (CH) 2010-09-23 US disclosed
US-20100240680-A1 Purine derivatives as a2a agonists NOVARTIS AG (CH) 2010-09-23 US disclosed
US-20100190784-A1 Organic Compounds NOVARTIS AG 2010-07-29 US disclosed
US-20100190784-A1 Organic Compounds NOVARTIS AG 2010-07-29 US disclosed
EP-1889846-A1 Purine derivatives as A2a agonists Novartis AG (CH) 2008-02-20 EP disclosed
WO-2008006563-A1 PURINE DERIVATIVES AS A2A AGONISTS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190784-A1 Organic Compounds CYP1B1, POLR2A, CYP1A1 KMT2A 1975/4885RAB9A 2001/4885GAA 1362/4885
US-20100240680-A1 Purine derivatives as a2a agonists ADORA2A, ADORA1, ADORA3 KMT2A 4032/4885RAB9A 2137/4885GAA 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.